Beam Therapeutics Q3 net loss wider than expected on higher R&D expenses

Beam Therapeutics

04/11/2025 12:23

Overview

Beam Therapeutics Q3 net loss misses analyst expectations

Company ended Q3 2025 with $1.1 bln in cash, supporting operations into 2028

Beam progressing with BEAM-302 and BEAM-101 clinical trials

Outlook

Beam expects to report BEAM-302 trial data in early 2026

Company plans to present BEACON trial data at ASH meeting in December 2025

Beam's cash runway expected to support operations into 2028

Result Drivers

CASH POSITION - Beam ended Q3 2025 with $1.1 bln in cash, supporting operations into 2028

R&D EXPENSES - Increased R&D expenses to $109.8 mln in Q3 2025, contributing to net loss

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 License and Collaboration Revenue
$9.69 mln
Q3 Net Income
Miss
-$112.72 mln
-$96.50 mln (11 Analysts)
Q3 Operating Income
Miss
-$126.81 mln
-$107 mln (11 Analysts)
Q3 Pretax Profit
Miss
-$112.72 mln
-$105.50 mln (9 Analysts)
Q3 Operating Expenses
$136.50 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 14 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Beam Therapeutics Inc is $42.50, about 42.9% above its November 3 closing price of $24.25

Press Release: ID:nGNXbt2k6Y

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)